According to a recent LinkedIn post from ViGenCell(바이젠셀), the company is participating in the ChinaBio™ Partnering Forum 2026 in Shanghai, described as a venue for expanding global partnering and licensing discussions. The post also directs readers to a Korean-language press release for further details on these business development activities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same LinkedIn post highlights domestic and international media coverage of ViGenCell’s selection for an oral presentation at the ASCO oncology conference, including articles in The Korea Herald and the Financial Times. This combination of active participation in a major partnering forum and scientific visibility at ASCO suggests a focus on advancing out-licensing and collaboration opportunities, which could influence the company’s pipeline monetization prospects and its positioning within the global cell and gene therapy market.